Structures by: Chadeayne A. R.
Total: 20
4-Hydroxy-<i>N</i>,<i>N</i>-di-<i>n</i>-propyltryptammonium chloride
C16H25N2O,Cl
IUCrData (2020) 5, 11 x201546
a=7.860(3)Å b=10.439(4)Å c=11.713(5)Å
α=76.236(14)° β=73.653(13)° γ=68.852(12)°
Bis{[2-(4-hydroxy-1<i>H</i>-indol-3-yl)ethyl]bis(propan-2-yl)azanium} but-2-enedioate tetrahydrate
C16H25N2O,0.5(C4H2O42),2(H2O)
IUCrData (2019) 4, 11 x191469
a=8.3495(8)Å b=12.5138(11)Å c=18.6631(17)Å
α=90° β=100.902(3)° γ=90°
<i>N</i>,<i>N</i>-Diallyl-5-methoxytryptamine
C17H22N2O
IUCrData (2020) 5, 4
a=6.1444(6)Å b=12.8514(13)Å c=19.3315(19)Å
α=90° β=91.626(3)° γ=90°
<i>N</i>-Allyl-<i>N</i>,<i>N</i>-dimethyltryptammonium iodide
0.5(C15H21N2),0.5(I)
Acta Crystallographica Section E (2020) 76, 8 1357-1360
a=7.3471(8)Å b=9.9672(9)Å c=10.9499(11)Å
α=90° β=94.671(3)° γ=90°
<i>N</i>,<i>N</i>-Dimethyl-<i>N</i>-<i>n</i>-propyltryptammonium iodide
C15H23N2,I
Acta Crystallographica Section E (2020) 76, 8 1357-1360
a=7.4471(6)Å b=9.9016(9)Å c=22.052(2)Å
α=90° β=94.184(3)° γ=90°
<i>N</i>-Ethyl-<i>N</i>-propyltryptammonium hydrofumarate
C15H23N2,C4H3O4
Acta Crystallographica Section E (2020) 76, 8 1201-1205
a=7.4839(8)Å b=14.1752(14)Å c=9.6461(10)Å
α=90° β=110.537(3)° γ=90°
<i>N</i>-Allyl-<i>N</i>-methyltryptammonium (MALT) hydrofumarate
C14H19N2,C4H3O4
Acta Crystallographica Section E (2020) 76, 8 1201-1205
a=7.9845(7)Å b=8.5641(6)Å c=25.649(2)Å
α=90° β=90° γ=90°
4-Hydroxy-<i>N</i>-methyltryptammonium fumarate
C11H15N2O,0.5(C4H2O42)
Acta Crystallographica Section E (2020) 76, 4 589-593
a=7.7363(10)Å b=9.7146(12)Å c=9.7854(13)Å
α=105.524(4)° β=110.554(4)° γ=97.167(4)°
4-Hydroxy-<i>N</i>-methyltryptamine
C11H14N2O
Acta Crystallographica Section E (2020) 76, 4 589-593
a=9.4060(16)Å b=8.8436(15)Å c=12.144(2)Å
α=90° β=100.601(7)° γ=90°
Bis{[2-(4-hydroxy-1<i>H</i>-indol-3-yl)ethyl](methyl)propan-2-ylazanium} but-2-enedioate
C14H21N2O,C2HO2
Acta Crystallographica Section E (2020) 76, 4 514-517
a=19.770(13)Å b=9.477(6)Å c=17.620(12)Å
α=90° β=105.78(2)° γ=90°
Bis(4-acetoxy-<i>N</i>,<i>N</i>-dimethyltryptammonium) fumarate
2C14H19N2O2,(C4H2O42)
Acta Crystallographica Section E (2019) 75, 6 900-902
a=8.3965(13)Å b=8.9879(14)Å c=12.0126(16)Å
α=101.730(5)° β=100.818(5)° γ=112.463(5)°
<i>N</i>-Isopropyl-<i>N</i>-methyltryptaminium fumarate
C14H21N2,C4H3O4
Acta Crystallographica Section E (2019) 75, 9 1316-1320
a=9.852(2)Å b=12.789(2)Å c=14.875(3)Å
α=90° β=106.932(7)° γ=90°
4-Hydroxy-<i>N</i>-isopropyl-<i>N</i>-methyltryptaminium fumarate monohydrate
C14H21N2O,C4H3O4,H2O
Acta Crystallographica Section E (2019) 75, 9 1316-1320
a=29.507(3)Å b=8.7445(8)Å c=17.3659(18)Å
α=90° β=123.389(3)° γ=90°
I,C15H21N2O2
I,C15H21N2O2
ACS omega (2020) 5, 27 16940-16943
a=7.8459(9)Å b=9.8098(12)Å c=11.0823(12)Å
α=90° β=101.069(3)° γ=90°
I,C13H19N2O
I,C13H19N2O
ACS omega (2020) 5, 27 16940-16943
a=11.3057(9)Å b=11.2370(10)Å c=12.7785(10)Å
α=90° β=113.087(2)° γ=90°
C54H126O6Si6Ta2
C54H126O6Si6Ta2
Inorganic Chemistry (2004) 43, 3421-3432
a=12.9177(16)Å b=13.4760(17)Å c=23.148(3)Å
α=82.096(3)° β=74.402(3)° γ=64.714(3)°
C54H126Cl2O6Si6Ta2
C54H126Cl2O6Si6Ta2
Inorganic Chemistry (2004) 43, 3421-3432
a=13.9922(8)Å b=25.2621(14)Å c=21.2191(11)Å
α=90.00° β=101.968(1)° γ=90.00°
[2-(4-Acetyloxy-1<i>H</i>-indol-3-yl)ethyl](methyl)ethylazanium 3-carboxyprop-2-enoate
C15H21N2O2,C4H3O4
Acta Crystallographica Section E (2021) 77, 2 101-106
a=7.9555(4)Å b=13.3696(7)Å c=9.9708(5)Å
α=90° β=112.874(2)° γ=90°
[2-(4-Acetyloxy-1<i>H</i>-indol-3-yl)ethyl](methyl)prop-2-enylazanium 3-carboxyprop-2-enoate
C16H21N2O2,C4H3O4
Acta Crystallographica Section E (2021) 77, 2 101-106
a=7.9702(4)Å b=14.1788(7)Å c=9.8035(5)Å
α=90° β=113.394(2)° γ=90°
Bis{[2-(4-acetyloxy-1<i>H</i>-indol-3-yl)ethyl]diprop-2-enylazanium} but-2-enedioate--(<i>E</i>)-butenedioic acid (1/1)
2(C18H23N2O2),C4H2O42,C4H4O4
Acta Crystallographica Section E (2021) 77, 2 101-106
a=23.6642(19)Å b=8.4204(7)Å c=23.4002(18)Å
α=90° β=111.614(2)° γ=90°